Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer

Inclusion Criteria: * Histologically- or cytologically- confirmed metastatic breast adenocarcinoma. * No previous chemotherapy treatment for metastatic disease. * No previous anthracycline treatment except as adjuvant therapy at least one year before. * Age 19-75 years old * Presence of measurable disease * Performance status 0-2 (WHO) * Adequate cardiac function (LVEF \>50%) without a recent (within 6 months) history of myocardial infraction and/or unstable or uncontrolled angina. * Adequate bone marrow(absolute neutrophil count \>1500/mm3, platelet count \>100.000/mm3, hemoglobin \>10gr/mm3), liver (bilirubin \<1.5 times upper limit of normal and SGOT/SGPT \<2 times upper limit of normal) and renal function (creatinine \<2mg/dl). * No previous radiotherapy to more than 25% of marrow-containing bones. * Written informed consent Exclusion Criteria: * Active brain metastases. * Psychiatric illness or social situation that would preclude study compliance * Other concurrent uncontrolled illness. * Other invasive malignancy within the past 5 years except of nonmelanoma skin cancer. * Positive pregnancy for premenopausal women. * Concurrent antineoplastic treatment e.g. hormonal therapy